FPC
VBIV

Falcon Point Capital’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Falcon Point Capital’s Portfolio VBIV Stock Details VBIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-3,260
Closed -$342K – 128
2018
Q1 		$342K Sell
3,260
-687
-17% -$82K 0.07% 101
2017
Q4 		$506K Sell
3,947
-2,583
-40% -$318K 0.09% 93
2017
Q3 		$674K Buy
+6,530
New +$784K 0.1% 91

Other funds holding VBIV

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
AS
Altshuler Shaham Tel Aviv, Israel $8.04B AUM 44.04% 1-Year Est. Return

Falcon Point Capital's VBIV Position: Q2 2018 in Review

Falcon Point Capital sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2018, closing a stake of 3,260 shares — an estimated $342K sold.

Falcon Point Capital first reported a position in VBIV in Q3 2017 and held it in 3 quarters. The position peaked at $674K in Q3 2017. 48 funds tracked by Wall St. Rank hold VBIV as of Q2 2018.

  • Falcon Point Capital reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2018 after selling out during the quarter.
  • Falcon Point Capital sold 3,260 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2018, an estimated $342K.
  • Falcon Point Capital first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q3 2017 and held it in 3 quarters.
  • Falcon Point Capital's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $674K in Q3 2017.
  • 48 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2018.

Based on Falcon Point Capital's 13F filing for Q2 2018, filed 7 Aug 2018.